Trial reportWorld journal of psychiatry2026
Protective effect of Guanxinning on antipsychotic-induced cardiac impairment in long-term hospitalized psychiatric patients.
Trial report in World journal of psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLong-term antipsychotic therapy in psychiatric patients carries significant cardiovascular risks, including QT interval prolongation, myocardial injury, and functional impairment. Guanxinning, a traditional Chinese medicine formulation, has demonstrated cardioprotective potential in preclinical studies, but clinical evidence in this population remains limited.
aimTo evaluate the cardioprotective effects of Guanxinning against antipsychotic-induced cardiac injury in long-term hospitalized psychiatric patients.
methodsA randomized, double-blind, placebo-controlled trial was conducted with 120 psychiatric inpatients receiving chronic antipsychotic therapy. Participants were allocated to: Intervention group: Conventional antipsychotics + Guanxinning tablets (0.38 g × 4 tablets, ter in die); Control group: Conventional antipsychotics + identical placebo; Cardiac assessments at baseline and 12 months included: Electrocardiography (corrected QT interval), echocardiography (left ventricular ejection fraction, left ventricular end-diastolic diameter), serum biomarkers (cardiac troponin I, B-type natriuretic peptide, superoxide dismutase, malondialdehyde, high-sensitivity C-reactive protein).
resultsCompared to controls, the Guanxinning group showed: Electrophysiological improvement: Corrected QT shortening (438 ± 25 milliseconds
conclusionGuanxinning significantly mitigates antipsychotic-induced cardiac injury in psychiatric patients, demonstrating: Normalization of electrophysiological parameters, Preservation of systolic/diastolic function, suppression of oxidative stress and inflammation. These findings support its clinical application as an adjunctive cardioprotective therapy, potentially through inhibition of myocardial apoptosis and antioxidant upregulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.